-

06:07:44 AM

MGNX Stock News

MGNX - Macrogenics Inc

11/17/22 6:10 PM

Nasdaq : MGNX

fda approval

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the

RHEA-AI

very positive

11/03/22 4:01 PM

Nasdaq : MGNX

earnings

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data in first

RHEA-AI

neutral

11/02/22 4:30 PM

Nasdaq : MGNX

conferences

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

RHEA-AI

neutral

10/26/22 4:30 PM

Nasdaq : MGNX

earnings

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

RHEA-AI

neutral

10/17/22 7:30 AM

Nasdaq : GILD, MGNX

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Gilead Sciences, Inc. and MacroGenics today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART ® platform, and two additional bispecific research programs. A leader in the bispecific antibody space,...

RHEA-AI

very positive

09/02/22 7:00 AM

Nasdaq : MGNX

conferences

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

RHEA-AI

neutral

08/08/22 4:01 PM

Nasdaq : MGNX

earnings

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 with

RHEA-AI

neutral

07/25/22 4:01 PM

Nasdaq : MGNX

earnings

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

RHEA-AI

neutral

07/08/22 4:30 PM

Nasdaq : MGNX

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022, the Company closed the

RHEA-AI

neutral

06/08/22 4:01 PM

Nasdaq : MGNX

conferences

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

MGNX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.macrogenics.com
CeoScott Koenig
Security nameMacrogenics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees370
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address9704 Medical Center Dr
StateMaryland
CityRockville
Zip20850-3343
CountryUS
Phone13012515172

About Macrogenics Inc

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.